Shire subsidiary sues Genentech and Chugai
Baxalta, a wholly-owned subsidiary of Shire, has filed a patent infringement complaint against Genentech and Chugai Pharmaceutical.
The case, which was filed on Thursday, May 4, at the US District Court for the District of Delaware, centres on a “humanised bispecific antibody”, which Genentech and Chugai have developed under the name emicizumab.
According to the complaint, Chugai and Genentech have collaborated since September 2015 to develop the antibody product.
In September 2015, Genentech announced that the Food and Drug Administration granted therapy designation to emicizumab for the treatment of haemophilia. According to Baxalta, this treatment infringed its US patent number 7,033,590.
Genentech allegedly intended to market emicizumab in the US under the brand Hemlibra, Hemleka, or Seitma, as it filed applications for these trademarks with the US Patent and Trademark Office in June 2015.
Baxalta has asked the court for judgment in its favour, as well as an injunction enjoining both Genentech and Chugai from selling emicizumab in the US.
It has also asked the court for costs and demanded a jury trial.
Join us for a FREE webinar - The Halo effect: walking the wilfulness tightrope - on May 16
Todays stories
Sanofi seeks to prevent Praluent injunction
Michael Best adds IP partner in Chicago
Federal Circuit reverses Suprep kit ruling
Sandoz SPC challenge unsuccessful
WHO to make biosimilars available in poor countries
Did you enjoy reading this story? Sign up to our free newsletter and get stories like this sent straight to your inbox.
